Citius Oncology (NASDAQ:CTOR) Stock Price Up 1.2% - What's Next?

Key Points

• Citius Oncology's stock price increased by 1.2% to $1.67, with a significant drop in trading volume compared to its average.
• Analysts have mixed ratings on the stock, with a current average rating of "Hold" and a target price set at $6.00.
• Institutional investors hold over 70% of Citius Oncology's shares, indicating significant confidence in the company's potential.

Citius Oncology, Inc. (NASDAQ:CTOR - Get Free Report)'s share price rose 1.2% during trading on Thursday . The stock traded as high as $1.74 and last traded at $1.67. Approximately 124,686 shares were traded during trading, a decline of 56% from the average daily volume of 285,824 shares. The stock had previously closed at $1.65.

Analysts Set New Price Targets

CTOR has been the subject of several research analyst reports. Weiss Ratings restated a "sell (d-)" rating on shares of Citius Oncology in a research note on Wednesday, October 8th. Wall Street Zen upgraded shares of Citius Oncology to a "hold" rating in a research note on Saturday, July 26th. Maxim Group raised shares of Citius Oncology from a "hold" rating to a "buy" rating and set a $6.00 target price on the stock in a report on Tuesday, September 23rd. Finally, Citigroup raised shares of Citius Oncology from a "hold" rating to a "buy" rating in a report on Tuesday, September 23rd. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of "Hold" and an average target price of $6.00.

Citius Oncology Stock Up 1.2%

The firm's 50-day simple moving average is $1.85 and its 200-day simple moving average is $1.72. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.02 and a current ratio of 0.35.

Institutional Trading of Citius Oncology

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC purchased a new stake in shares of Citius Oncology during the second quarter valued at approximately $465,000. Geode Capital Management LLC raised its stake in shares of Citius Oncology by 179.0% during the second quarter. Geode Capital Management LLC now owns 57,297 shares of the company's stock valued at $249,000 after acquiring an additional 36,758 shares during the last quarter. Arkadios Wealth Advisors bought a new position in shares of Citius Oncology during the second quarter valued at about $51,000. Finally, Bank of America Corp DE raised its stake in shares of Citius Oncology by 5,256.9% during the second quarter. Bank of America Corp DE now owns 8,571 shares of the company's stock valued at $37,000 after acquiring an additional 8,411 shares during the last quarter. Institutional investors own 70.52% of the company's stock.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.